AUPH Q4 2022 Earnings — Aurinia Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

AUPHAurinia Pharmaceuticals Inc.

$2B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$28M+21.5% YoY

Gross Profit

$27M95.2% margin

Operating Income

-$28M-98.8% margin

Net Income

-$26M-91.6% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

-49.0%

Cash Flow

Operating Cash Flow

$10M

Free Cash Flow

$10M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$471M

Total Liabilities

$65M

Stockholders' Equity

$405M

Cash & Equivalents

$94M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$28M	$23M	+21.5%
Gross Profit	$27M	$23M	+18.1%
Operating Income	-$28M	-$33M	+14.1%
Net Income	-$26M	-$33M	+21.8%

Revenue Segments

Product

$28M100%

License

$109,0000%